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On 22 August 2015 the Chinese National 
Health and Family Planning Commission 
(NHFPC; the former Ministry of Health, 
MOH) have issued the long awaited ‘draft’ 
regulation on clinical research and applica-
tions that involve human stem cells [1–3]. 
In China, regulation usually starts out as 
a draft or trial regulation. A draft regula-
tion should be regarded as valid as formal 
regulation, but it is flexible enough to leave 
space for change. The document announces 
the central elements of a regulatory foun-
dation for the clinical translation of stem 
cell-based medicinal products and proce-
dures. What does China’s future regulation 
for clinical stem cell trials look like? What 
challenges can be expected with regard to 
its implementation? And what impacts will 
the regulation have for domestic researchers, 
clinics and corporations in China and at an 
international level?
Overview of the draft regulation
The draft regulation applies to the clinical 
use of human autologous and allogeneic stem 
cells that are manipulated in vitro, with the 
exception of the routine transplantations of 
hematopoietic stem cells and of clinical trials 
that use stem cells that are affirmed as phar-
maceutical products. Stem cell treatments 
have to pass through methodical clinical 
studies and follow from systematic preclini-
cal evidence. These trials must comply with 
the Chinese ‘Quality Control Standards for 
Clinical Drug Trials’ (the Chinese good clin-
ical practice standards), which has guided 
the approval of new drugs by the China Food 
and Drug Administration (CFDA) since 
2007. Furthermore, first-in-human clinical 
trials must be based on systematic evidence 
of preclinical research proving the therapeu-
tic value and safety of a candidate treatment 
in appropriate animal models.
The standards and technical procedures 
for the collection, manufacturing and stor-
age of stem cells for clinical use are laid down 
in the ‘Stem Cell Preparations Quality Con-
trol and Preclinical Research Guidelines’, a 
supplementary document published by the 
CFDA, which also specifies the required 
criteria for safety and efficacy assessment 
in the context of preclinical studies. Only 
level 3 hospitals – the highest ranked hos-
pital category in China – are permitted to 
conduct stem cell clinical trials. To qualify, 
such hospitals must have established institu-
tions for research, healthcare and teaching, 
and be in possession of the relevant profes-
sional qualifications. Hospitals must have 
ethics and academic committees capable of 
dealing adequately with adverse effects and 
preventing high-risk applications. Moreover, 
hospitals are required to establish stem cell 
preparation facilities that are compliant with 
international GMP standards.
Investigators applying for stem cell clinical 
trials must do so at provincial branches of the 
NHFPC and CFDA, and register the trials 
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online at the Chinese Medicine Registry and Manage-
ment System. The NHFPC and CFDAs will jointly 
review the projects at a provincial level with the help 
of specifically formed expert committees. These com-
mittees do not only review incoming applications but 
also will conduct on-site verification and evaluation of 
academic institutions, ethics committees and project 
management. If a clinical trial application is accepted, 
Phase I of the trial can go ahead. Clinical trial prog-
ress reports must be submitted to the authorities on a 
regular basis, and after each phase investigators need 
to report the research results to the provincial agencies. 
Based on these reports, decisions are made about pro-
gression to the next phase and ultimately about routine 
clinical application.
The regulation seeks to protect the interests of 
patients in the following ways. First of all, clinical 
investigators may not charge money for patients taking 
part in clinical studies, and hospitals are not allowed 
to advertise stem cell trials as treatments. Hospitals are 
required to fully inform patients of the potential risks 
of the research involved, and to arrange insurance cov-
erage for human subjects for projects involving a high 
level of risk. In case of emergency, life-saving facilities 
need to be in place. Moreover, serious adverse events 
must be reported to the hospital ethics committee and 
the provincial health authorities, and will result in the 
immediate halt of the research project and withdrawal 
of approval for the application of the stem cell therapy 
concerned.
Stem cell clinical trials must be conducted in 
accordance with the ‘2007 Interim Regulation on the 
Review of Biomedical Research Involving Human 
Subjects’ of the MOH (now NHFPC), and the ‘Drug 
Administration Law’, issued by the MOH in 2001. 
Clinical trials using human embryonic stem cells 
must harvest and process the cells in line with the 
‘Guiding Principles for the Ethics for Human Embry-
onic Stem Cell Research’, a joint regulation issued in 
2003 by the Ministry of Science and Technology and 
the MOH. With the new draft regulation stem cell-
based treatments are no longer regulated as class III 
medical technology in accordance with the 2009 
regulation for clinical stem cell applications [4], which 
indicates that the former regulation is no longer valid.
Medical institutions and staff who violate regulatory 
provisions are directly held responsible in accordance 
with specifically designed penal procedures. The provin-
cial branches of the NHFPC and CFDA have the author-
ity to suspend stem cell trials and to punish investigators 
and staff in line with appropriate laws and regulations.
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China has invested heavily into stem cell medicine in 
recent years. This has resulted in a growing body of 
publications and the development of new candidate 
therapies [5]. Simultaneously, due to a permissive regula-
tory environment for clinical stem cell applications, the 
country has witnessed the mushrooming of commer-
cial stem cell clinics. Between 2002 and 2012, China 
became a global hub for the sale of unproven clinical 
for-profit interventions [6]. A first attempt to control this 
situation was undertaken in 2009 in the context of a 
new regulation for medical technologies [7]. However, 
because of disagreements within the health authori-
ties on feasible implementation pathways, this regula-
tion was never enforced for stem cell research and the 
number of unproven stem cell interventions was widely 
reported to grow [6–8]. In 2012, the MOH undertook a 
renewed regulatory effort by introducing a notification, 
which stipulated that all medical institutions without 
prior approval from the MOH or the CFDA must stop 
clinical stem cell procedures. This notification had lim-
ited effect, mainly on state-supported scientific institu-
tions. An article in Nature reported that 3 months after 
the ban, numerous clinics in China were continuing 
their services [9]. Then, in March 2013, the NHFPC 
published three inter-related draft regulations for pub-
lic comments. These documents announced stringent 
controls on experimental stem cell interventions and 
emphasized clinical translation through systematic 
clinical trials overseen by the Chinese health authorities.
Elements of the 2013 regulation have now been 
incorporated in the regulatory documents published in 
August 2015. The 2015 ‘draft’ regulation indicates an 
important step toward the improved governance and 
review of stem cell clinical research and applications 
in China. With the enforcement of systematic clinical 
studies required to comply with scientific principles, 
standardization, transparency and the improved protec-
tion of research subjects, the CFDA and NHFPC have 
established a framework intended to cater to the needs 
of researchers in China and internationally. The regula-
tion rejects the use of unproven experimental for-profit 
interventions with stem cells [5], while introducing a 
clear strategy toward more responsible forms of clinical 
translation. The prohibition to advertise unproven stem 
cell treatment and charging patients for taking part in 
experimental studies alone could potentially result in 
the permanent halt of experimental for-profit interven-
tions in a large number of hospitals that have profited 
“The prohibition to advertise unproven stem cell 
treatment and charging patients for taking part 
in experimental studies alone could potentially 
result in the permanent halt of experimental 
for-profit interventions in a large number of 
hospitals.” 
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from unclear regulations for years [8]. Institutions that 
work under the publicized rules can be expected to 
raise methodological standards, improve the validity of 
research data and subject patients to less risk.
However, the actual impact of the regulation depends 
on its enforcement and implementation. By sharing 
administrative duties for review and certification of 
clinical stem cell research and applications between 
provincial NHFPC and CFDA branches, and by train-
ing specialist staff and expert committees to operate at 
the provincial level, China’s health authorities create a 
regulatory infrastructure that promises to hit its tar-
get. The document’s grounding in the country’s ‘Drug 
Administration Law’ and the backing of its stipulations 
by punitive measures reinforces this impression. Imple-
mentation, nonetheless, can be expected to be a difficult 
and gradual process, with several challenges along the 
way. A first challenge will be to train sufficient numbers 
of staff, and to recruit well-qualified experts for inde-
pendent review, so that incoming applications can be 
dealt with in a reliable and simultaneously efficient way. 
A further challenge concerns the geographical size of 
China, the country’s large number of medical institu-
tions, and the lucrative business opportunities that have 
evolved in the stem cell field in recent years [10]. In the 
light of the well-established national and international 
networks of for-profit stem cell therapy providers in 
China [7], it will be difficult to control for-profit stem 
cell clinics. The problem of implementing the regula-
tion to established institutions that seek to approve stem 
cell clinical trials is different from that of controlling 
stem cell clinics. While the new draft regulation delegit-
imizes unapproved for-profit stem cell interventions and 
provides a legal basis to close down such clinics, it does 
not provide concrete details on how the enforcement of 
such controls might occur. While the Chinese authori-
ties in the last years have sporadically clamped down on 
for-profit stem cell clinics [7], it is unclear whether the 
resources, administrative infrastructure and the politi-
cal will can be mobilized to counter these clinics on a 
large scale and on a nation-wide level. Enforcement of 
the regulation in the context of level 3 hospitals, on the 
other hand, can be expected to be successful: China’s 
elite stem cell researchers have long-since demanded 
a kind of regulation that can legitimize their research 
and resulting clinical applications. It remains to be seen, 
however, how tightly oversight procedures for clinical 
stem cell applications will be organized and whether the 
number of staff and available resources will be sufficient 
to assure dependable implementation.
Moreover, variation can be expected in the interpre-
tation of regulation and policies among the provinces. 
Will these divergent interpretations thwart homogenous 
implementation? Despite possible variation across prov-
inces, it is clear in the draft regulation that all research 
and commercial activities fall under the responsibility of 
the main units of the NHFPC and the CFDA in Bei-
jing, which prohibit unauthorized for-profit interven-
tions at the national level. Exemptions from the national 
standard at the provincial level (which has proven a hin-
drance for the effective regulation of autologous stem 
cell treatments in the USA [11]) are not possible.
It is also not clear to what extent the regulation affect 
practices in army and police hospitals, which have their 
own regulatory bodies and where much of the com-
mercial stem cell activities have been located in recent 
years [12]. Much will depend on the political prioriti-
zation of tackling all experimental stem cell therapy 
providers, ranging from small for-profit providers to 
powerful military organizations.
The promise of greater dependability of approval 
procedures for the clinical development of stem cell 
treatments and greater compatibility with interna-
tional procedures should be a relief to many stem 
cell scientists in China. The absence of a functioning 
regulatory framework for clinical stem cell research for 
many years has deprived researchers and R&D compa-
nies of the possibility to apply for the official registra-
tion of newly developed candidate treatments [6]. It has 
also limited the opportunity for building international 
clinical research collaborations [13]. By introducing sys-
tematic approval procedures for stem cell clinical trials 
the forthcoming regulation will strengthen domestic 
innovation trajectories, facilitate collaborations with 
foreign researchers and also allow for joint applica-
tions for the approval of candidate therapies at drug 
regulatory authorities in China and in other countries.
The draft regulation’s commitment to systematic 
preclinical studies, clinical trials, reliable quality con-
trols, the Chinese good clinical practice standards, 
Good Manufacturing Practice (GMP) and external 
review by independent expert committees promises 
to create congruence with both, the benchmarks set 
out in the ‘Guidelines for the Clinical Translation of 
Stem Cells’ of the International Society for Stem Cell 
Research [14], and the standards for clinical stem cell 
research handled by the US FDA and the EMA.
Open questions
The new draft regulation provides a basis to define exper-
imental for profit interventions with stem cells in China 
as illegal and to investigate and punish stem cell clinics 
“It remains to be seen how tightly oversight 
procedures for clinical stem cell applications will 
be organized and whether the number of staff 
and available resources will be sufficient to assure 
dependable implementation.” 
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that operate outside the supervision of the NHFCP and 
the CFDA. The focus of this new regulation, however, is 
exclusively on the governance of clinical research. It does 
not stipulate any details on how the transition from clini-
cal trials to routine clinical use and market approval shall 
be handled. This leaves many questions to be answered 
that will be crucial for corporations and international 
collaborations that strive for the joint application of stem 
cell treatments at drug regulatory authorities in China 
and other countries. Because information on market-
ing conditions is absent in the publicized regulation, it is 
extremely difficult to discuss its implications for interna-
tional collaborations. A possible explanation to the lack 
of information on market approval in the current regula-
tion is that no agreement on this point has been reached 
yet between involved stakeholders.
Unclear is also what procedures will be handled for 
the clinical use of stem cells that are affirmed as phar-
maceutical products, and also what criteria the NHFCP 
and the CFDA handle in order to define pharmaceuti-
cal stem cell products. Clearly designated subcategories 
of different types of stem cell interventions have not 
yet been published. However, such definitions will be 
of crucial importance to determine the relevant regula-
tory authority (the NHFCP or the CFDA, or different 
subunits). The fact that the CFDA is closely involved in 
the drafting and implementation of this regulation sug-
gests that at least some stem cell based applications will 
be classified as medicinal products. No matter how, the 
fact that this important point remains undefined sug-
gests that harmonization with regulatory agencies in 
the USA, Europe and other highly developed countries 
is still a long way off. These uncertainties might cause 
confusion for biotech companies, especially those that 
produce stem cells as quantifiable batch products from 
a single cell line, as for instance Geron has done with 
its human embryonic stem cell product [11]. Another 
question is what type of clinical studies the NHFCP 
and CFDA require to allow the go-ahead from clinic 
to the market and routine use. While in a former, now 
invalid draft of the new regulation that was issued for 
public consultation in 2013 it was stated that system-
atic controlled Phase I–III trials would be required [15], 
the current regulation only speaks of clinical trials that 
shall be conducted according to scientific principles. 
Do China’s health regulators leave this question delib-
erately open, so as to have the flexibility to follow the 
current Japanese model rather than the USA or EU 
model, which allows for conditional and time-limited 
market approval after successful clinical studies with 
relatively small number of patients [16]? Another issue 
that remains unclear is whether the new regulation 
in China leaves space for the conduct of experimen-
tal clinical interventions with stem cells outside of the 
format of the clinical trial (for instance as a ‘last resort’ 
treatment in individual patients after all existing inter-
ventions have failed) and how these forms of clinical 
experimentation will be reviewed and approved. A 
further question is how the regulation will impact the 
affordability of stem cell trials. The requirement of sys-
tematic preclinical research, the availability of GMP 
laboratories and clinical translation through system-
atic clinical trials will significantly increase the costs 
of clinical translation. Accordingly, the introduction 
of the new regulations may have drawbacks for less 
well-endowed research institutes [7]. With increased 
costs and a system that allows clinical studies solely 
in qualified tier three hospitals, only a limited num-
ber of investigators and research institutions will be 
enabled to conduct clinical stem cell trials. The result-
ing unequal access to financial resources may redefine 
opportunities to clinical innovations in the stem cell 
field. It remains to be seen whether this new situation 
will reignite a new brain drain to the private sector or 
abroad.
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“The promise of greater dependability of ap-
proval procedures for the clinical development 
of stem cell treatments and greater compatibility 
with international procedures should be a relief 
to many stem cell scientists in China.”
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